Potential blockbusters in the Alzheimer’s, Parkinson’s and lung cancer fields will produce much-awaited results this quarter, as the Swiss major reported solid Q3 growth.
Roche has enjoyed a strong year of rebuilding its portfolio and sales, but three major readouts in the final quarter could either sweeten or sour 2024 for the company.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
